Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction

Diabetes

Volumn 66, Issue 8, 2017, Pages 2230-2240

  Sassoon, Daniel J ^a   Tune, Johnathan D ^a   Mather, Kieren J ^a   Noblet, Jillian N ^a   Eagleson, Mackenzie A ^a   Conteh, Abass M ^a   Sturek, Joshua T ^a   Goodwill, Adam G ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; DOBUTAMINE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; SODIUM CHLORIDE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDIABETIC AGENT;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETERIZATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; CORRELATION ANALYSIS; DIASTOLE; DOSE RESPONSE; DRUG EFFECT; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PERFORMANCE; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; OBESITY; PORCINE MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REST; SIGNAL TRANSDUCTION; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; AGONISTS; ANIMAL; COMPLICATION; DRUG EFFECTS; HEART; HEART LEFT VENTRICLE FUNCTION; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PIG; TREATMENT OUTCOME;

ANIMALS; CARDIAC OUTPUT; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEART; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MYOCARDIAL INFARCTION; OBESITY; RECEPTORS, ADRENERGIC, BETA-1; SWINE; SYMPATHOMIMETICS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 85025581702     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-1206     Document Type: Article

References (47)

1. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013;3:e001986
2. Goodwill AG, Tune JD, Noblet JN, et al. Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. Basic Res Cardiol 2014;109:426
3. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510
4. Mogensen UM, Andersson C, Fosbøl EL, et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus-A retrospective nationwide study. Diabetes Obes Metab 2014;16:1001-1008
5. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247-2257
6. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322
7. Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014;56: 369-381
8. Mathew B, Francis L, Kayalar A, Cone J. Obesity: effects on cardiovascular disease and its diagnosis. J Am Board Fam Med 2008;21:562-568
9. Qiao Q, Grandy S, Hiller J, Kostev K. Clinical and patient-related variables associated with initiating GLP-1 receptor agonist therapy in type 2 diabetes patients in primary care in Germany. PLoS One 2016;11:e0152281
10. Moberly SP, Mather KJ, Berwick ZC, et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol 2013;108:365
11. Gejl M, Søndergaard HM, Stecher C, et al. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97: E1165-E1169
12. Sassoon DJ, Goodwill AG, Noblet JN, et al. Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism. Basic Res Cardiol 2016;111:43
13. Goodwill AG, Mather KJ, Conteh AM, Sassoon DJ, Noblet JN, Tune JD. Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev Endocr Metab Disord 2014;15:209-217
14. Haddock RE, Hill CE. Sympathetic overdrive in obesity involves purinergic hyperactivity in the resistance vasculature. J Physiol 2011;589:3289-3307
15. Berwick ZC, Dick GM, O'Leary HA, et al. Contribution of electromechanical coupling between Kv and Cav1.2 channels to coronary dysfunction in obesity. Basic Res Cardiol 2013;108:370
16. Suga H, Hayashi T, Shirahata M. Ventricular systolic pressure-volume area as predictor of cardiac oxygen consumption. Am J Physiol 1981;240: H39-H44
17. Westerhof N. Cardiac work and efficiency. Cardiovasc Res 2000;48:4-7
18. Poudyal H. Mechanisms for the cardiovascular effects of glucagon-like peptide-1. Acta Physiol (Oxf) 2016;216:277-313
19. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994;94:623-630
20. Potz BA, Sabe AA, Elmadhun NY, et al. Glycogen synthase kinase 3b inhibition improves myocardial angiogenesis and perfusion in a swine model of metabolic syndrome. J Am Heart Assoc 2016;5:e003694
21. Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009;9:31
22. Ekström K, Dalsgaard M, Iversen K, et al. Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs. Scand Cardiovasc J 2017;51:8-14
23. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-983
24. Connelly KA, Advani A, Zhang Y, et al. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: role of stromal cellderived factor-1a. J Diabetes 2016;8:63-75
25. van den Wijngaard JP, Schulten H, van Horssen P, et al. Porcine coronary collateral formation in the absence of a pressure gradient remote of the ischemic border zone. Am J Physiol Heart Circ Physiol 2011;300:H1930-H1937
26. Margulies KB, Hernandez AF, Redfield MM, et al.; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 2016;316:500-508
27. Lønborg J, Kelbæk H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012;5:288-295
28. Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013;33:2252-2260
29. Lønborg J, Vejlstrup N, Kelbæk H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33: 1491-1499
30. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015;38: 132-139
31. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: A guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol 2005;289:H501-H512
32. Suga H. Total mechanical energy of a ventricle model and cardiac oxygen consumption. Am J Physiol 1979;236:H498-H505
33. Suga H. Ventricular energetics. Physiol Rev 1990;70:247-277
34. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006;55:466-473
35. Knaapen P, Germans T, Knuuti J, et al. Myocardial energetics and efficiency: current status of the noninvasive approach. Circulation 2007;115: 918-927
36. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207-258
37. Hansen J, Brock B, Bøtker HE, Gjedde A, Rungby J, Gejl M. Impact of glucagonlike peptide-1 on myocardial glucose metabolism revisited. Rev Endocr Metab Disord 2014;15:219-231
38. Hall JL, Stanley WC, Lopaschuk GD, et al. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol 1996;271:H2320-H2329
39. Bristow MR, Gilbert EM, Abraham WT, et al.; MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816
40. Sharma V, Dhillon P, Wambolt R, et al. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol 2008;294:H1609-H1620
41. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473-483
42. Kernis SJ, Harjai KJ, Stone GW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004;43:1773-1779
43. Grover GJ, Kostis JB, Weiss HR, Li JK, Kovacs T, Kedem J. Effect of betaadrenoceptor stimulation or blockade on regional myocardial function and regional O2 consumption during myocardial ischemia. Arch Int Pharmacodyn Ther 1988;291: 68-87
44. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-569
45. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 1997;80:7L-14L
46. ter Keurs HE. The interaction of Ca2+ with sarcomeric proteins: role in function and dysfunction of the heart. Am J Physiol Heart Circ Physiol 2012; 302:H38-H50
47. Noyan-Ashraf MH, Shikatani EA, Schuiki I, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 2013;127:74-85